Natural Methods To Control Cholesterol

References

1. Pencina MJ, Navar-Boggan AM, D'Agostino RB, et al. Application of new cholesterol guidelines to a population-based sample*. N Engl J Med*. 2014;370:1422–31.
2. Institute of Medicine (US) Committee on a National Surveillance System for Cardiovascular and Select Chronic Diseases. *A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases*. Washington (DC): National Academies Press (US); 2011.
3. Available at: http://www.heart.org/idc/groups/ahamah-public/@wcm/@sop/@smd/documents/downloadable/ucm_470704.pdf. Accessed February 2, 2015.
4. Yamashita S, Tsubakio-Yamamoto K, Ohama T, Nakagawa-Toyama Y, Nishida M. Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions. *J Atheroscler Thromb*. 2010 May;17(5):436-51.
5. Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. *J Lipid Res*. 2010 Jun;51(6):1546-53.
6. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. *Neuro Endocrinol Lett.* 2009;30(4):470-6.
7. Molyneux SL, Florkowski CM, George PM, et al. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. *J Am Coll Cardiol.* 2008 Oct 28;52(18):1435-41.
8. Rondanelli M, Giacosa A, Opizzi A, et al. Beneficial effects of artichoke leaf extract supplementation on increasing HDL-cholesterol in subjects with primary mild hypercholesterolaemia: a double-blind, randomized, placebo-controlled trial. *Int J Food Sci Nutr.* 2013 Feb;64(1):7-15.
9. Evans M, Rumberger JA, Azumano I, Napolitano JJ, Citrolo D, Kamiya T. Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation. *Vasc Health Risk Manag.* 2014;10:89-100.
10. Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. *Am J Cardiovasc Drugs.* 2010;10(1):11-28.
11. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. *Toxicol Lett.* 2002 Mar 10;128(1-3):159-68.
12. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. *Diabetes Care.* 2009 Oct;32(10):1924-9.
13. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet.* 2010 Feb 27;375(9716):735-42.
14. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. *Jama.* 2011 Jun 22;305(24):2556-64.
15. Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. *J Am Coll Cardiol.* 2011 Apr 5;57(14):1535-45.
16. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. *Arch Intern Med.* 2012 Jan 23;172(2):144-52.
17. Barter P. HDL-C: role as a risk modifier. *Atheroscler Suppl*. 2011 Nov;12(3):267-70.
18. Barter, P. The role of HDL-cholesterol in preventing atherosclerotic disease. *Eur Heart J Supp*. 2005;7(suppl F):F4-F8.
19. Parolini C, Marchesi M, Chiesa G. HDL therapy for the treatment of cardiovascular diseases. *Curr Vasc Pharmacol*. 2009 Oct;7(4):550-6.
20. Andersson LO. Pharmacology of apolipoprotein A-I. *Curr Opin Lipidol.* 1997 Aug;8(4):225-8.
21. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. *Circulation.* 1995 May 1;91(9):2488-96.
22. Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. *Circulation.* 1999 Aug 10;100(6):594-8.
23. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. *Am J Med.* 1977 May;62(5):707-14.
24. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med.* 1998 Jul 23;339(4):229-34.
25. Kawashiri MA, Maugeais C, Rader DJ. High-density lipoprotein metabolism: molecular targets for new therapies for atherosclerosis. *Curr Atheroscler Rep.* 2000 Sep;2(5):363-72.

26. Mooradian AD. Cardiovascular disease in type 2 diabetes mellitus: current management guidelines. *Arch Intern Med.* 2003 Jan 13;163(1):33-40.
27. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. *N Engl J Med.* 1999 Aug 5;341(6):410-8.
28. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). *Bmj.* 1998 Mar 14;316(7134):823-8.
29. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. *Am J Cardiol.* 2000 Dec 21;86(12a):19l-22l.
30. Goldenberg I, Benderly M, Sidi R, et al. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). *Am J Cardiol.* 2009 Jan 1;103(1):41-5.
31. Ramos PA, Guerra AR, Guerreiro O, et al. Lipophilic extracts of Cynara cardunculus L. var. altilis (DC): a source of valuable bioactive terpenic compounds. *J Agric Food Chem.* 2013 Sep 4;61(35):8420-9.
32. Brown JE, Rice-Evans CA. Luteolin-rich artichoke extract protects low density lipoprotein from oxidation in vitro. *Free Radic Res.* 1998 Sep;29(3):247-55.
33. Fritsche J, Beindorff CM, Dachtler M, Zhang H, Lammers JG. Isolation, characterization and determination of minor artichoke (Cynara scolymus L.) leaf extract compounds. *Eur Food Res Technol*. 2002;215:149-57.
34. Jiménez-Escrig A, Dragsted LO, Daneshvar B, Pulido R, Saura-Calixto F. In vitro antioxidant activities of edible artichoke (Cynara scolymus L.) and effect on biomarkers of antioxidants in rats. *J Agric Food Chem*. 2003 Aug 27;51(18):5540-5.
35. Gebhardt R. Inhibition of cholesterol biosynthesis in HepG2 cells by artichoke extracts is reinforced by glucosidase pretreatment. *Phytother Res.* 2002 Jun;16(4):368-72.
36. Qiang Z, Lee SO, Ye Z, Wu X, Hendrich S. Artichoke extract lowered plasma cholesterol and increased fecal bile acids in Golden Syrian hamsters. *Phytother Res.* 2012 Jul;26(7):1048-52.
37. Englisch W, Beckers C, Unkauf M, Ruepp M, Zinserling V. Efficacy of Artichoke dry extract in patients with hyperlipoproteinemia. *Arzneimittelforschung.* 2000 Mar;50(3):260-5.
38. Lupattelli G, Marchesi S, Lombardini R, et al. Artichoke juice improves endothelial function in hyperlipemia. *Life Sci.* 2004 Dec 31;76(7):775-82.
39. Bundy R, Walker AF, Middleton RW, Wallis C, Simpson HC. Artichoke leaf extract (Cynara scolymus) reduces plasma cholesterol in otherwise healthy hypercholesterolemic adults: a randomized, double blind placebo controlled trial. *Phytomedicine.* 2008 Sep;15(9):668-75.
40. Rondanelli M, Riva A, Sala P, Giacosa A. Pilot study on the efficacy of 200 mg daily dose of PYCRINIL on glyco-lipidic parameters in adult subjects with mild hypercholesterolemia: University of Pavia, Department of Public Health, Experimental and Forensic Medicine, Section of Human Nutrition, Azienda di Servizi alla Persona, Pavia, Italy; 2014.
41. Matsuyama A, Sakai N, Hiraoka H, Hirano K, Yamashita S. Cell surface-expressed moesin-like HDL/apoA-I binding protein promotes cholesterol efflux from human macrophages. *J Lipid Res*. 2006 Jan;47(1):78-86.
42. Gouedard C, Barouki R, Morel Y. Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism. *Mol Cell Biol.* 2004 Jun;24(12):5209-22.
43. van der Gaag MS, van Tol A, Scheek LM, et al. Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. *Atherosclerosis.* 1999 Dec;147(2):405-10.
44. Hsu JC, Tanaka K, Inayama I, Ohtani S. Effects of pantethine on lipogenesis and CO2 production in the isolated hepatocytes of the chick (Gallus domesticus). *Comp Biochem Physiol Comp Physiol.* 1992 Jul;102(3):569-72.
45. Carrara P, Matturri L, Galbussera M, Lovati MR, Franceschini G, Sirtori CR. Pantethine reduces plasma cholesterol and the severity of arterial lesions in experimental hypercholesterolemic rabbits. *Atherosclerosis.* 1984 Dec;53(3):255-64.
46. Prisco D, Rogasi PG, Matucci M, et al. Effect of oral treatment with pantethine on platelet and plasma phospholipids in IIa hyperlipoproteinemia. *Angiology.* 1987 Mar;38(3):241-7.
47. Gaddi A, Descovich GC, Noseda G, et al. Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia. *Atherosclerosis.* 1984 Jan;50(1):73-83.
48. Bertolini S, Donati C, Elicio N, et al. Lipoprotein changes induced by pantethine in hyperlipoproteinemic patients: adults and children. *Int J Clin Pharmacol Ther Toxicol.* 1986 Nov;24(11):630-7.
49. Arsenio L, Bodria P, Magnati G, Strata A, Trovato R. Effectiveness of long-term treatment with pantethine in patients with dyslipidemia. *Clin Ther.* 1986;8(5):537-45.
50. Coronel F, Tornero F, Torrente J, et al. Treatment of hyperlipemia in diabetic patients on dialysis with a physiological substance. *Am J Nephrol.* 1991;11(1):32-6.
51. Rumberger JA, Napolitano J, Azumano I, Kamiya T, Evans M. Pantethine, a derivative of vitamin B(5) used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low- to

moderate-cardiovascular risk North American subjects: a triple-blinded placebo and diet-controlled investigation. *Nutr Res.* 2011 Aug;31(8):608-15.
52. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. *J Gen Intern Med*. 2004 Jun;19(6):638-45.
53. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med*. 2005 Apr 4;352(14):142535.
54. Kellner-Weibel G, Luke SJ, Rothblat GH. Cytotoxic cellular cholesterol is selectively removed by apoA-I via ABCA1. *Atherosclerosis*. 2003 Dec;171(2):235-43.
55. Bachorik PS, Lovejoy KL, Carroll MD, Johnson CL (1997) Apolipoprotein B and AI distribution in the United States, 1988–1991: results of the National Health and Nutrition Examination Survey III (NHANES III). *Clin Chem*. 1997 Dec;43(12):2364-78.
56. Mackness MI, Durrington PN, Mackness B. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. *Am J Cardiovasc Drugs.* 2004;4(4):211-7.
57. Cagnin A, Leon A, Vianello D, et al. LDL density and oxidation are modulated by PON1 promoter genotype in patients with Alzheimer's disease. *J Alzheimers Dis*. 2013;34(2):377-85.
58. Nus M, Frances F, Librelotto J, Canales A, et al. Arylesterase activity and antioxidant status depend on PON1-Q192R and PON1-L55M polymorphisms in subjects with increased risk of cardiovascular disease consuming walnut-enriched meat. *J Nutr.* 2007 Jul;137(7):1783-8.
59. Elshourbagy NA, Meyers HV, Abdel-Meguid SS. Cholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemia. *Med Princ Pract.* 2014;23(2):99-111.
60. Walker AE, Eskurza I, Pierce GL, Gates PE, Seals DR. Modulation of vascular endothelial function by low-density lipoprotein cholesterol with aging: influence of habitual exercise. *Am J Hypertens.* 2009 Mar;22(3):250-6.
61. Available at: http://www.lef.org/magazine/2010/9/No-Cure-for-Heart-Disease/Page-01. Accessed February 12, 2015.
62. Available at: http://www.lef.org/magazine/2011/6/The-FDA-Most-Heinous-Drug-Approval/Page-02. Accessed February 12, 2015.
63. Nussey S, Whitehead S*. Endocrinology: An Integrated Approach*. Oxford: BIOS Scientific Publishers; 2001. Chapter 1: Principles of Endocrinology.
64. Ballantyne CM, Pitt B, Loscalzo J, Cain VA, Raichlen JS. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial). *Am J Cardiol.* 2013 Feb 15;111(4):506-9.
65. Horvath Z, Vecsei L. Current medical aspects of pantethine. *Ideggyogy Sz.* 2009 Jul 30;62(7-8):220-9.
66. Kelly GS. Pantethine: A Review of its Biochemistry and Therapeutic Applicaitons. *Alt Med Rev.* 1997;2(5):365-76.
67. Branca D, Scutari G, Siliprandi N. Pantethine and pantothenate effect on the CoA content of rat liver. *Int J Vitam Nutr Res.* 1984;54(2-3):211-6.